Vir Biotechnology

Vir Biotechnology is a San Francisco-based clinical-stage immunology company originally founded to apply modern biological tools to infectious disease. Sources describe an origin in which large pharmaceutical companies had reduced investment in vaccines, antibacterials and antivirals, and Vir was assembled to build or acquire platforms — including T- and B-cell biology, RNAi and vaccine technologies — and direct them at diseases such as hepatitis B, influenza A, HIV, tuberculosis and SARS-CoV-2 [0]. The company has been associated with four technology platforms and a pipeline of candidates identified as VIR-1111, VIR-2020, VIR-2218, VIR-2218 + PEG-IFN, VIR-2482, VIR-2703, VIR-3434, VIR-7831 and VIR-7832 [0][1].

Vir's profile rose during the COVID-19 pandemic. Working with GSK, it developed the antibody sotrovimab (marketed as Xevudy), which received U.S. FDA emergency authorization in 2021; the authorization was later lost as newer viral variants reduced its potency [3][4]. Vir had entered the coronavirus field with antibodies isolated from recovered SARS patients, targeting a conserved region of the viral stem [0]. Earlier, the company raised hundreds of millions of dollars privately, secured a partnership with Alnylam Pharmaceuticals, and helped bring an Ebola antiviral to market [3].

Since 2023 the company has undergone successive restructurings. A December 2023 reorganization cut 75 positions and closed R&D facilities in Missouri and Oregon, retaining R&D in Switzerland and San Francisco, in order to prioritize chronic hepatitis delta and hepatitis B programs [3]. In August 2024 Vir discontinued most of its virology work — including COVID-19 and influenza programs and its T-cell-based viral vector platform — cut roughly 25% of staff (about 140 roles), and in-licensed three dual-masked T-cell engagers from Sanofi (SAR446309, HER2xCD3; SAR446329, PSMAxCD3; SAR446368, EGFRxCD3), marking a pivot toward oncology [2]. Vir is listed on Nasdaq under the ticker VIR [1].

Founding story

Vir's early technology traces to a predecessor company, Tomegavax. Bob More was introduced to that technology through his work with the Bill and Melinda Gates Foundation and, as a Tomegavax board member, helped orchestrate the acquisition of the company and the subsequent formation of Vir [0]. The stated founding rationale was that the biotech and pharmaceutical industries lacked a major infectious disease player after decades of declining investment in vaccines, antibacterials and antivirals, and that tools such as RNAi, CRISPR, novel vaccine platforms and AI-based drug discovery had not been applied with purpose to infectious disease [0]. Sources give founding dates of 2016 [1][3] and, in one account, 2017 [0]; listed founders include Larry Corey, Klaus Frueh, Jay Parrish and Louis Picker [1].

Business model

Vir develops therapeutic candidates in-house and through in-licensing and partnerships with larger pharmaceutical companies. Its COVID-19 antibody was co-developed and commercialized with GSK, and it holds a collaboration with Alnylam Pharmaceuticals [3]. Under the 2024 Sanofi agreement, Vir pays an undisclosed upfront amount plus development, regulatory and commercial net sales-based milestones, with Sanofi entitled to tiered royalties on worldwide net sales of any resulting product, in exchange for exclusive worldwide licenses to three T-cell engagers [2].

Revenue derives from collaboration and product-related arrangements rather than a broad commercial portfolio; Vir recorded $3.1 million of revenue in the second quarter of 2024, down from $3.8 million a year earlier [2], and one aggregator reports FY2025 revenue of $68.6 million [1].

Traction

Vir advanced several drug candidates into clinical trials within its first three years [0] and obtained FDA emergency use authorization in 2021 for the GSK-partnered COVID-19 antibody sotrovimab, later withdrawn [3][4]. As of June 30, 2024 it held $1.43 billion in cash, cash equivalents and investments [2], down from $1.7 billion as of the third quarter of 2023 [3]. Headcount peaked in mid-2023 at roughly 635 and was expected to end 2024 at about 435 [2]; an aggregator lists 367 employees and 12 open roles [1].

Latest developments

In August 2024 Vir announced a strategic overhaul: it discontinued COVID-19 and influenza work and its T-cell-based viral vector platform, limited virology to hepatitis B and D, cut about 140 roles (25% of staff), and licensed three dual-masked T-cell engagers from Sanofi, with SAR446368 due to begin a Phase 1 study in the first quarter of 2025. The company projected about $50 million in annual workforce cost savings from 2025 plus a further $50 million from phasing out programs, against restructuring charges of $11–13 million [2].